Four months after two Endocyte drug candidates stumbled in early-stage studies, sparking a corporate shakeup, the company has signed a deal landing an experimental prostate cancer treatment that it says is ready for Phase 3 clinical trials. West Lafayette, IN-based Endocyte (NASDAQ: ECYT) says it paid $12 million up front to German biochemicals company ABX […]

Pfizer just got some badly needed good news for its newly acquired cancer drug Xtandi. After watching sales sink right after it acquired the therapy and all of Medivation for $14 billion, researchers say the drug cleared the Phase III study for non-metastatic, castration resistant prostate cancer. And at least one prominent analyst says that’s […]

What’s Hot at ESMO 2017?
September 7, 2017

MADRID — The revolution in cancer therapy represented by targeted therapy and immunotherapy will be continued at Europe’s leading oncology meeting, when new data will show that the drugs are effective not only in the palliative setting but also in earlier stages of the disease. The European Society for Medical Oncology (ESMO) 2017 Congress, which […]

Armune BioScience has developed the peer-reviewed and validated prostate-cancer-risk-assessment technology Apifiny®—a cancer specific, non-PSA blood test that may aid clinicians in the assessment of risk for the presence of prostate cancer. We are delighted present a follow up interview with David Esposito, President and Chief Executive Officer at Armune BioScience, Kalamazoo, Michigan. Our original interview with […]

Greater selectivity for PLK1, potency, oral bioavailability and short half-life underscore PCM-075’s potential as safe and effective treatment for solid tumor and hematological malignancies. SAN DIEGO, July 25, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ:  TROV), a precision medicine biotechnology company, today announced the publication of clinical results from a Phase 1 dose escalation study of […]


Myriad Genetics’ Prolaris® Test Accurately Predicts the 10-Year Risk of Metastases in Men Treated for Prostate Cancer Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The […]


OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium OncoGenex Pharmaceuticals, Inc. (OGXI) today announced that apatorsen results from two randomized Phase 2 clinical trials were presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers […]


Minomic Announces Clinical Study Update for MILGa in Prostate, Bladder and Pancreatic Cancers Minomic International Ltd (Minomic) is an immuno-oncology company specializing in therapeutics and diagnostics for solid tumors, including prostate, bladder and pancreas. The Company today announced that it has completed enrollment and dosing of the first three patients in its pioneering clinical […]


Cancer Targeted Technology Commences Phase I Clinical Trial of CTT1057, a Diagnostic Imaging Agent for Prostate Cancer Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on small molecules that target pivotal enzyme targets on cancer, announced that a Phase I clinical trial has commenced in men with high risk metastatic prostate cancer. […]

Nicholas Vogelzang, MD: Unmet Needs in Oncology
October 24, 2016

Klara Czobor:  Our first question Dr. Vogelzang is what malignancy do you primarily treat in your practice? Dr. Vogelzang: Being a general oncologist in private practice, I get to treat many different malignancies. I primarily treat prostate, kidney, and bladder cancer. I also treat patients with testicular cancer and sarcoma, as well as smaller numbers […]